Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

New research by Cedars-Sinai investigators supports evidence that social factors, such as unemployment, financial difficulties, racial discrimination and other stressors, affect an individual's health. Getty Images

News | Stroke

Racism, Stress and Stroke Outcomes

November 22, 2022 — investigators from the Department of Neurology at Cedars-Sinai have new information on stroke-relate ...

November 22, 2022

Trial Evaluates FDA-Designated Breakthrough Therapy for Patients Who Lack Treatment Options

News | Heart Failure

Impulse Dynamics Announces First Patient Enrolled in AIM HIGHer — Implantable Device Trial to Treat Heart Failure in Higher EF Population

November 22, 2022 — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with ...

November 22, 2022

Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled clinical tools have to be easily available and used.

News | Artificial Intelligence

High adopters of AI-enabled screening tool are more likely to diagnose left ventricular dysfunction than low adopters, Mayo Clinic study finds

November 21, 2022 — Artificial intelligence can improve diagnosis and treatment for patients, but first the AI-enabled ...

November 21, 2022

News | Hypertension

Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

November 21, 2022

Justin Balko, PharmD, PhD, Ingram Associate Professor of Cancer Research, and a co-corresponding author of the study. Credit: Vanderbilt University Medical Center

News | Heart Failure

Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

November 22, 2022 — Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

November 21, 2022

Figure 1. Flow chart of machine learning workflow. A machine learning (ML) model for the prediction of vessel-specific ischemia was built, trained, and tuned in the NXT trial (Analysis of Coronary Blood Flow using CT Angiography: Next Steps). The model’s predictive performance was evaluated in the PACIFIC trial (Prospective Comparison of Cardiac Positron Emission Tomography [PET]/Computed Tomography [CT]‚ Single Photon Emission Computed Tomography [SPECT]/CT Perfusion Imaging and CT Coronary Angiography wit

News | Computed Tomography (CT)

AI Tool Predicts Reduced Blood Flow to the Heart

November 17, 2022 — Cedars-Sinai investigators and colleagues have developed an artificial intelligence (AI) tool that ...

November 17, 2022

Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.

News | Peripheral Artery Disease (PAD)

Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia

November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral ...

November 15, 2022

When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.

News | Heart Failure

Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 — When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

November 14, 2022

Less complex heart patients may benefit, but not without risk

News | Pediatric Cardiology

Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery

November 14, 2022 — For more than four decades, doctors have been split on whether giving steroids during a pediatric ...

November 14, 2022

Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System

News | Antiplatelet and Anticoagulation Therapies

Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 — Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

November 14, 2022

The "Trending Topics at Sessions 2022" panel of experts featured Manesh R. Patel, MD, FACC, FAHA, Chair of the Committee on AHA 2022 Scientific Sessions, to review highlights and lessons learned from the event.

News | AHA

November 14, 2022 — The American Hospital Association Scientific Sessions 2022, held Nov. 5-7 in Chicago, IL, presented ...

November 14, 2022

Investigators Compared AFib Patients Treated with Catheter Ablation to Those Treated with Anti-arrhythmic Drugs Only

News | Atrial Fibrillation

Study Finds Catheter Ablation Significantly Lowers Risk of Dementia in Patients with Atrial Fibrillation

November 10, 2022 — Biosense Webster, Inc., the global leader in cardiac arrhythmia treatment and part of Johnson & ...

November 10, 2022

When the SARS-CoV-2 protein Nsp6 is made in a fruit fly heart (center), the heart has structural defects compared to a normal heart without the viral protein (left). When fruit fly hearts with the viral Nsp6 protein are given the metabolism changing drug 2DG (right), the hearts begin to look more normal than the ones with the viral protein that do not have the drug. Image courtesy of Zhe Han at UMSOM

News | Coronavirus (COVID-19)

How a SARS-CoV-2 Virus Protein Damages the Heart

November 10, 2022 — Researchers at the University of Maryland School of Medicine’s (UMSOM) Center for Precision Disease ...

November 10, 2022

Findings from the BEST-CLI trial presented at the American Heart Association Scientific Sessions (AHA2022) indicate optimal treatment for patients with limb-threatening ischemia.

News | AHA

BEST-CLI Clinical Trial Focuses on Optimal Treatment for Limb-Threatening Ischemia

November 10, 2022 – Significant findings from the clinical trial, known as “BEST-CLI — Best Endovascular versus Best ...

November 10, 2022